8.62
Precedente Chiudi:
$8.23
Aprire:
$8.23
Volume 24 ore:
870.98K
Relative Volume:
0.77
Capitalizzazione di mercato:
$494.31M
Reddito:
$89.04M
Utile/perdita netta:
$-241.08M
Rapporto P/E:
-1.6388
EPS:
-5.26
Flusso di cassa netto:
$-194.72M
1 W Prestazione:
+0.94%
1M Prestazione:
-16.71%
6M Prestazione:
+9.67%
1 anno Prestazione:
-19.81%
Regenxbio Inc Stock (RGNX) Company Profile
Nome
Regenxbio Inc
Settore
Industria
Telefono
240-552-8181
Indirizzo
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Confronta RGNX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
RGNX
Regenxbio Inc
|
8.62 | 494.31M | 89.04M | -241.08M | -194.72M | -5.26 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-02-11 | Downgrade | Goldman | Buy → Neutral |
2025-02-07 | Ripresa | Raymond James | Outperform |
2024-11-15 | Ripresa | Morgan Stanley | Overweight |
2024-10-10 | Ripresa | Raymond James | Outperform |
2024-06-07 | Iniziato | Goldman | Buy |
2024-03-11 | Iniziato | H.C. Wainwright | Buy |
2024-03-08 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
2024-03-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
2024-02-21 | Ripresa | Raymond James | Outperform |
2023-11-01 | Iniziato | Stifel | Buy |
2023-06-02 | Iniziato | Robert W. Baird | Outperform |
2022-06-23 | Iniziato | Berenberg | Buy |
2021-12-15 | Iniziato | Wedbush | Neutral |
2021-10-19 | Ripresa | Morgan Stanley | Overweight |
2021-01-06 | Aggiornamento | Raymond James | Outperform → Strong Buy |
2020-12-16 | Iniziato | UBS | Buy |
2020-06-25 | Ripresa | BofA/Merrill | Buy |
2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
2019-08-20 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
2019-06-18 | Reiterato | Chardan Capital Markets | Buy |
2019-06-14 | Ripresa | Raymond James | Outperform |
2019-06-05 | Reiterato | Chardan Capital Markets | Buy |
2019-02-25 | Aggiornamento | Evercore ISI | In-line → Outperform |
2019-02-05 | Aggiornamento | Raymond James | Outperform → Strong Buy |
2018-12-17 | Reiterato | Chardan Capital Markets | Buy |
2018-11-08 | Reiterato | BofA/Merrill | Neutral |
2018-08-08 | Reiterato | Chardan Capital Markets | Buy |
2018-07-23 | Downgrade | BofA/Merrill | Buy → Neutral |
2018-07-10 | Reiterato | Chardan Capital Markets | Buy |
2018-05-09 | Reiterato | Barclays | Overweight |
2018-04-09 | Reiterato | Chardan Capital Markets | Buy |
2018-03-12 | Downgrade | Evercore ISI | Outperform → In-line |
2018-02-13 | Iniziato | Mizuho | Neutral |
2017-11-09 | Ripresa | Morgan Stanley | Overweight |
Mostra tutto
Regenxbio Inc Borsa (RGNX) Ultime notizie
Regenxbio (RGNX) Maintains Strong Outlook Amid Competitor Safety Concerns | RGNX Stock News - GuruFocus
REGENXBIO announces royalty monetization agreement for up to $250M - MSN
REGENXBIO (RGNX) Prepares for Potential $4M Warrant Cash Influx - GuruFocus
Regenxbio (RGNX) Proposes Sale of Over 268,000 Shares | RGNX Stock News - GuruFocus
Regenxbio (RGNX) Maintains Buy Rating with $52 Price Target | RGNX Stock News - GuruFocus
A Glimpse Into The Expert Outlook On Regenxbio Through 8 Analysts - Benzinga
Promising RGX-202 Trial Results Justify Buy Rating for RegenXBio Amid Market Skepticism - TipRanks
REGENXBIO updates Phase 1/2 data for Duchenne candidate - MSN
Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome - Seeking Alpha
H.C. WAINWRIGHT MAINTAINS BUY RATING ON REGENXBIO STOCK AFTER POSITIVE TRIAL DATA - Investing.com Nigeria
Duchenne gene therapy interim trial outcomes "striking" - MarketScreener
Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update - BioPharma Dive
RegeNXBio shares fall, despite positive new data on RGX-202 - The Pharma Letter
REGENXBIO reports progress in Duchenne treatment trial By Investing.com - Investing.com South Africa
Regenxbio’s Duchenne gene therapy data positive as shares falter - BioWorld MedTech
New Regenxbio DMD Data Support Gene Therapy Accelerated Approval - insights.citeline.com
Stifel reiterates Buy rating on Regenxbio stock after trial data By Investing.com - Investing.com Nigeria
Stifel reiterates Buy rating on Regenxbio stock after trial data - Investing.com Australia
REGENXBIO reports new positive functional data from phase I/II AFFINITY Duchenne® trial of RGX-202 - Pipelinereview
Regenxbio’s Gene Therapy Helps Kids with Deadly Muscle Disease - Bloomberg
Transcript : REGENXBIO Inc.Special Call - MarketScreener
Regenxbio (RGNX) Reports Positive Data for RGX-202 Gene Therapy Trial - GuruFocus
Regenxbio (RGNX) Reports Promising Interim Results for Duchenne Therapy | RGNX Stock News - GuruFocus
REGENXBIO reports progress in Duchenne treatment trial - Investing.com Australia
REGENXBIO stock in focus after data for Duchenne drug (RGNX) - Seeking Alpha
Regenxbio Reports New Positive Functional Data From Phase I/Ii Affinity Duchenne® Trial Of Rgx-202 - MarketScreener
REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II A - GuruFocus
REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 | RGNX Stock News - GuruFocus
REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 - PR Newswire
RegenXBio Holds 2025 Annual Stockholders Meeting - TipRanks
ProShare Advisors LLC Boosts Stake in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
Bank of America Corp DE Reduces Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202 - Eagle-Tribune
REGENXBIO to Host Webcast Discussing Interim Functional Data fro - GuruFocus
REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202 | RGNX Stock News - GuruFocus
Leerink Partnrs Weighs in on REGENXBIO FY2026 Earnings - Defense World
Ameriprise Financial Inc. Has $2.20 Million Stake in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $775,000 Stock Position in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
D. E. Shaw & Co. Inc. Raises Position in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
REGENXBIO’s SWOT analysis: gene therapy firm’s stock poised for growth By Investing.com - Investing.com UK
REGENXBIO’s SWOT analysis: gene therapy firm’s stock poised for growth - Investing.com Australia
REGENXBIO Inc. (NASDAQ:RGNX) Shares Bought by Deutsche Bank AG - Defense World
Finance Watch: Public Company Fundraising Sank Across The Board In Q1 - insights.citeline.com
REGENXBIO’s $250 Million Royalty Bond Agreement with HealthCare Royalty - Global Legal Chronicle
Coave Therapeutics Establishes New Scientific Advisory Board to Accelerate Innovation in Genetic Medicines for Eye and CNS Diseases - GlobeNewswire Inc.
Regenxbio Inc Azioni (RGNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Regenxbio Inc Azioni (RGNX) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Mills Kenneth T. | Director |
May 12 '25 |
Sale |
7.91 |
20,602 |
163,046 |
475,103 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):